Shots:

• The approval is based on pivotal P-III VICTORIA trial involves assessing of Verquvo (2.5mg- 5mg & 10mg) vs PBO in 5-050 adult patients with symptomatic CHF and LVEF less than 45%- following a worsening HF event
• The study met the primary efficacy objective based on a time-to-event analysis & showed a 4.2% reduction in annualized absolute risk. The 1EPs is time to the first event of CV death or hospitalization for HF @median follow-up of 11 mos.
• Verquvo is the first soluble guanylate cyclase stimulator- approved to treat HF

 ­ Ref: Business Wire| Image: Merck